/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Icecure Medical Ltd share price today is $0.7, up 2.97%. The stock opened at $0.6676 against the previous close of $0.669, with an intraday high of $0.71 and low of $0.6676.

style

pb-0

Icecure Medical Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.7 0.0297(2.97%) ICCM at 13 Mar 2026 01:33 PM Medical Devices

Lowest Today 0.6676

Highest Today 0.71

Today’s Open 0.6676

Prev. Close 0.669

52 Week High 1.50

52 Week Low 0.54

Day’s Range: Low 0.6676 High 0.71

52-Week Range: Low 0.54 High 1.50

Icecure Medical Ltd Institutional Holdings

Icecure Medical Ltd Market Status

Strong Buy: 1

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Icecure Medical Ltd Fundamentals

Market Cap 46.14 M

PB Ratio 4.9577

PE Ratio 0.0

Enterprise Value 36.42 M

Total Assets 12.58 M

Volume 444810

Icecure Medical Ltd Company Financials

Annual Revenue FY23:2913000 2.9M, FY22:3085000 3.1M, FY21:4138000 4.1M, FY20:4084527 4.1M, FY19:1657618 1.7M

Annual Profit FY23:1192000 1.2M, FY22:1445000 1.4M, FY21:2195000 2.2M, FY20:2658332 2.7M, FY19:576412 0.6M

Annual Net worth FY23:-15609000 -15.6M, FY22:-17217000 -17.2M, FY21:-10066000 -10.1M, FY20:-4777099 -4.8M, FY19:-4760310 -4.8M

Quarterly Revenue Q3/2025:850000 0.9M, Q2/2025:525000 0.5M, Q1/2025:725000 0.7M, Q3/2024:662000 0.7M, Q2/2024:1011000 1.0M

Quarterly Profit Q3/2025:277000 0.3M, Q2/2025:131000 0.1M, Q1/2025:218000 0.2M, Q3/2024:235000 0.2M, Q2/2024:530000 0.5M

Quarterly Net worth Q3/2025:-3859000 -3.9M, Q2/2025:-3364000 -3.4M, Q1/2025:-3588000 -3.6M, Q3/2024:-4149000 -4.1M, Q2/2024:-3081000 -3.1M

About Icecure Medical Ltd & investment objective

Company Information IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Organisation Medical Devices

Employees 64

Industry Medical Devices

CEO Mr. Eyal Shamir

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*